Otonomy Starting Phase 1 Trial in 2015 for Tinnitus

I think @NatureHiker was referring to the chairman and co-founder, Jay Lichter. Please correct me if I'm wrong.

Taken from this link (emphasis mine):
"In 2008, Jay Lichter, Ph.D., a partner at Avalon Ventures and biotechnology industry veteran, experienced his first severe attack of vertigo. While driving, he became severely disoriented and had to pull to the side of the road. After multiple doctor visits, he was diagnosed with Ménière’s disease and quickly experienced the limitations of available treatments. With his physician, Jeffrey Harris, M.D., Ph.D., chief of the division of otolaryngology-head and neck surgery at the University of California, San Diego, and several other experts in the field of otology, Dr. Lichter founded Otonomy to bring new treatment options to patients with otic (ear) disorders."

 

My bad not a hedge fund manager just a investor/CEO/chair board member/whatever is the correct business phraseology.

I do know that he's suffered from Tinnitus for a while even before he was diagnosed with menieres.

http://www.sandiegouniontribune.com...ul-route-to-starting-2013apr21-htmlstory.html

 

So I understand this is the first farmaceutical trial to improve the chronic tinnitus target in the last years...

 

Is this treatment given for chronic tinnitus ?(more than 6months ?Am101 was only for recent tinnitus )
Not for recent one ? Are you sure ?
I wrote to this company I would like to try it in the phase 2 of clinical trials... But I'm french and I don't know if they can include me.... And they answered me that they didn't know yet what criteria of tinnitus include for the study... (Sorry for my approximated english)

 

This trial is for everybody with T.

 

OTO-311 = Gacyclidine

AM-101 = S-Ketamine (Esketamine)

 

OTO-311 is a so-called NMDA receptor antagonist - though differentiated from AM-101
Esketamine is a "non-competitive NMDA antagonist" whereas Gacyclidine is one
"Un-competitive blocker NMDA antagonist". They therefore have both the same pharmacological target, but work in a slightly different way.

We must therefore assume that both AM-101 and OTO-311 are geared towards
Acute inner ear tinnitus

 

Does anyome know if OTO-311 clinical trials will be run only in USA or in Europe as well?